Jay Siegel, MD, is the chief biotechnology officer - Shareholder.com

lunchlexicographerΒιοτεχνολογία

1 Δεκ 2012 (πριν από 4 χρόνια και 8 μήνες)

244 εμφανίσεις

Jay P. Siegel, M.D.
Chief Biotechnology Officer
Johnson & Johnson Pharmaceuticals and Medical Devices & Diagnostics Groups

Jay Siegel, M.D., is the chief biotechnology officer for both the Pharmaceuticals
and Medical Devices & Diagnostics segments of Johnson & Johnson, a position to
which he was named in March 2009. He leads an organization responsible for
expanding and managing the Company’s extensive biotechnology capabilities and
applying them to the discovery and development of new products in partnership with all
therapeutic areas across Pharmaceuticals, Surgical Care and Comprehensive Care
groups. In addition, he has oversight of biologics pharmaceutical development and
marketed product support, biologics clinical pharmacology sciences, biologics
toxicology, biopharmaceutical discovery and biologics CMC regulatory.
Prior to his current role, Siegel was the group president of Research &
Development for Pharmaceuticals, with oversight of research and development in
biotechnology, immunology and oncology. He also served as President of Centocor
Research & Development, Inc.
Siegel joined Johnson & Johnson in 2003 as president, Centocor Research &
Development, Inc., and the following year assumed additional responsibility as group
president, Research & Development, Pharmaceuticals, with oversight responsibility for
various companies and functions within the organization.
Prior to joining Johnson & Johnson, Siegel spent 20 years at the FDA Center for
Biologics Evaluation & Research in positions of increasing responsibility regulating the
biotechnology industry. From 1995 to 2002, he served as head of the FDA Office of
Therapeutics Research and Review, where he led a team overseeing the
biopharmaceutical therapeutics industry.
Siegel received a B.S. in Biology from California Institute of Technology and an
M.D. from Stanford University. He trained in Internal Medicine at the University of
California, San Francisco, and in Infectious Diseases and Immunology at Stanford
University. He has authored numerous publications in the areas of clinical trial design,
biotechnology, and immunology.